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Abstract
Background: Voriconazole concentrations display a large variability, which cannot completely be explained by known
factors. We investigated the relationships of voriconazole concentration with patient-specific variables and concomitant
medication to identify clinical factors affecting voriconazole clearance.
Methods: A retrospective chart review of voriconazole trough concentration, laboratory data, and concomitant
medication in patients was performed. The concentration/dose ratio (C/D-ratio) was assessed as a surrogate
marker of total clearance by dividing voriconazole concentration by daily dose per kg of body weight.
Results: A total of 77 samples from 63 patients were obtained. In multiple linear regression analysis, increased
C-reactive protein (CRP) level (p < 0.05) and decreased albumin (Alb) level (p < 0.05) were associated with
significantly increased C/D-ratio of voriconazole, and coadministration with a glucocorticoid was associated
with significantly (p < 0.05) decreased C/D-ratio of voriconazole (adjusted r2 = 0.31). Regarding CRP and Alb, receiver
operating characteristic curve analysis indicated that increased CRP level and decreased Alb level were significant
predictors of toxic trough concentration of voriconazole. For CRP, area under the curve (AUC) and cutoff value were
0.71 (95 % confidence interval (CI), 0.57–0.86, p < 0.01) and 4.7 mg/dl, respectively. For Alb, AUC and cutoff value were
0.68 (95 % CI, 0.53–0.82, p < 0.05) and 2.7 g/dl, respectively. A significant difference was seen in voriconazole trough
concentration between patients with hepatotoxicity and those without (5.69 μg/ml vs 3.0 μg/ml, p < 0.001).
Conclusion: Coadministration of glucocorticoid and inflammation, reflected by elevated CRP level and
hypoalbuminemia, are associated with voriconazole clearance. We propose that early measurement of voriconazole
concentration before the plateau phase will lead to avoidance of a toxic voriconazole level in patients with elevated
CRP level and hypoalbuminemia, although further studies are needed to confirm our findings.
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Background
The triazole antifungal voriconazole is widely used in the
treatment of invasive fungal infections, such as invasive
aspergillosis, candidemia, and pulmonary cryptococcosis,
except for zygomycosis [1–4]. Voriconazole exhibits a
nonlinear pharmacokinetics profile and is metabolized pri-
marily by the cytochrome P450 family enzyme CYP2C19
and, to lesser extent, CYP3A4 and CYP2C9 [1–4]. Allelic
polymorphisms of CYP2C19 have been shown to be the
most important determinants of the clearance efficiency
of vorizonazole [3, 5]. In Japanese, the rate of poor
metabolizers of CYP2C19 has been shown to be 15–20 %,
a higher figure than that of other races [6]. This raises
the necessity of blood concentration measurement for
Japanese to monitor efficacy and toxicity in the clinical
setting. There have been some reports on the relation-
ships between efficacy and toxicity of voriconazole and
its plasma concentrations. Target trough concentration
of therapeutic response is > 1–2 μg/ml [1, 3, 4, 7–9],
and prophylaxis is > 1.5 μg/ml [3]. To avoid side effects,
such as visual disturbance, neurotoxicity, and hepato-
toxicity, the target trough concentration is < 4–6 μg/ml
[1, 3, 4, 7–10]. Invasive fungal infections commonly
appear among immunocompromised patients receiving
concomitant medication for primary disease and/or
bacterial infection. Many of them have critically ill condi-
tions and polypharmacy, which possibly alter voriconazole
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concentration and clearance. Accordingly, to identify clin-
ical factors affecting voriconazole clearance, we investi-
gated the relationships of voriconazole concentration with
patient-specific variables and concomitant medication.
Methods
Patient enrollment and data collection
Patients who received voriconazole orally and had at least
one voriconazole trough concentration measurement
during therapy at Kyoto-Katsura Hospital, Japan, between
June 2010 and October 2015 were eligible for inclusion.
Patient-specific variables were collected retrospectively
including sex, age, body weight, body mass index (BMI),
laboratory data, purpose of voriconazole administration,
and diagnosis and treatment department. Laboratory data
included serum albumin (Alb), creatinine clearance (Ccr),
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), total bilirubin (T-Bil), alkaline phosphatase
(ALP), γ-glutamyl transpeptitase (γGTP), and C-reactive
protein (CRP). Ccr was estimated by using the Cockcroft-
Gault Formula [11]. Laboratory data at voriconazole
trough concentration measurement were used for analysis.
Daily dose, voriconazole trough concentration, the number
of days between blood sample collection and initial dose
were collected. Patients were excluded if: (a) they received
voriconazole intravenously even once to avoid unknown
covariates between orally and intravenously; (b) they re-
ceived concomitant rifabutin, rifampicin, carbamazepine,
phenytoin, or antiretroviral drugs; (c) they required dialysis
since the uremic substances, which should accumulate in
the blood of those patients, may alter the pharmacokinetics
of voriconazole; or (d) the number of days between blood
sample collection and initial voriconazole administration
with loading dose is 2 or less, or that without loading dose
is 4 or less, because the concentration did not reach a
steady state [3, 4]. Affect of concomitant glucocorticoid
(over 5 mg equivalent prednisolone as a daily dose) and
macrolide was analyzed in all patients, because those medi-
cations can interact with voriconazole pharmacokinetically
[9, 12, 13]. Cases in which the voriconazole dose was chan-
ged, or the above-mentioned concomitant medications
were started or discontinued, were regarded as separate
cases. Visual disturbance such as photophobia, blurred
vision, neurotoxicity such as drowsiness, insomnia, halluci-
nations, disturbance of consciousness, and hepatotoxicity
were evaluated as adverse events. Hepatotoxicity was
defined as ≥ grade 2 in results of liver function tests (AST,
ALT, T-Bil, ALP, and γGTP) within 14 days after initiation
of voriconazole administration or changing voriconazole
dosage, according to Common Terminology Criteria for
Adverse Events (CTCAE), version 4.0, since some of ALP
and γGTP values in the patients were over normal range
(about grade 1) before the voriconazole therapy. We used
voriconazole concentration at the time of occurrence of
toxicity in the patients with adverse event, whereas the
maximum concentration in the patients without adverse
event for the analysis of relationship between adverse
events and voriconazole concentration. All voriconazole
concentration data were collected from a central referral
laboratory (SRL Inc., Tokyo, Japan). A validated high-
performance liquid chromatography (HPLC) assay was
used to measure voriconazole concentrations [14].
The study was performed in accordance with the
Declaration of Helsinki and its amendments, and the
protocol was approved by the Ethics Committee of
Kyoto-Katsura Hospital.
Analysis of voriconazole pharmacokinetics
The concentration/dose ratio (C/D-ratio) was used as a
surrogate marker of total clearance by dividing voricona-
zole concentration by daily dose per kg of body weight.
Statistical analysis
Univariate linear regression analysis was used to esti-
mate relationships between C/D-ratio of voriconazole
and patient-specific continuous variables, and the
unpaired t test was used to compare voriconazole con-
centration and C/D-ratio of voriconazole between two
independent groups. Multiple linear regression analysis
was applied to identify factors that contribute to the
variability in C/D-ratio of voriconazole; a step-down
selection model was obtained using stepwise regression
with a p value of 0.25 as the inclusion criterion. The
diagnostic properties and cutoff values of independent
variables by multiple linear regression analysis were
cross-sectionally evaluated by a receiver operating
characteristic (ROC) curve. Outcome for diagnostic
properties was voriconazole trough concentration
exceeding 4 μg/ml, defined as a toxic level according to
the results of meta-analysis by Hamada et al. [8]. JMP®9
software was used for all analyses and a p value less
than 0.05 was regarded as statistically significant.
Results
Patient characteristics
A total of 77 samples from 63 patients were obtained in
the present study (Table 1). Eligible patients were elderly,
with a mean age of 70.8. Mean daily maintenance dose
and mean body weight were 273 mg and 49.7 kg, respect-
ively. The mean dosage is close to, but slightly lower than
the recommend daily oral dose on the package insert [15]
for patients with a body weight ≥ 40 kg (300–400 mg).
This may be caused by the suggestion by the clinical
pharmacist to the prescription doctors to reduce the
voriconazole dosage, since the pharmacist had
experienced higher concentration of voriconazole in
patients with higher CRP values, empirically. Twenty-
eight patients received glucocorticoid as a concomitant
Dote et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:10 Page 2 of 6
medication and most of them (23. 82 %) received
prednisolone.
Factors affecting voriconazole concentration and
clearance
Significant correlation was found between adminis-
tered dosage and trough concentration of voricona-
zole (r2 = 0.14, p < 0.001), (Fig. 1). Mean (SD) C/D-
ratio significantly decreased from 0.66 (0.42) to 0.43
(0.33) by concomitant administration with glucocortic-
oid (p = 0.01) (Fig. 2). Effect of concomitant macrolide on
C/D-ratio was not conducted because only two patients
was administered erythromycin. Significant correlations
were found between C/D-ratio of voriconazole and Alb
(r2 = 0.16, p < 0.01), CRP (r2 = 0.26, p < 0.0001). Alb, CRP,
and age (p = 0.07) were treated as continuous variables
and glucocorticoid use was treated as a dichotomous
variable in multiple linear regression analysis. Increased
CRP level and decreased Alb level were significantly
associated with increased C/D-ratio of voriconazole, and
coadministration with a glucocorticoid was significantly
associated with decreased C/D-ratio of voriconazole
(adjusted r2 = 0.31) (Table 2). We did a post-hoc analysis
of the effect of coadministration with a glucocorticoid on
interpatient variability of voriconazole concentration in
three patients (Table 3). C/D-ratio was considerably
decreased by glucocorticoid administration in all three
patients.
Cutoff values of factors causing toxic level of
voriconazole concentration
Multiple linear regression analysis indicated that CRP and
Alb were the factors affecting voriconazole clearance.
ROC curve analysis indicated that increased CRP level
and decreased Alb level were significant predictors of
toxic trough concentration of voriconazole: A) CRP - area
under the curve (AUC) 0.71 (95 % confidence interval
[CI], 0.57–0.86, p < 0.01), cutoff value 4.7 mg/dl (sensitiv-
ity 60.9 %, specificity 82.7 %); B) Alb - AUC 0.68 (95 % CI,
Table 1 Patient characteristics
Mean (SD)
Male/Female 50/13
Age (yr) 70.8 (11.0)
Body Weight (kg) 49.7 (9.5)
Body Mass Index (kg/m2) 19.0 (2.9)
Albumin (g/dl)a 2.7 (0.7)
Creatinine clearance (ml/min)a 67.4 (31.9)
AST (IU/L)a 32.9 (28.6)
ALT (IU/L)a 32.9 (35.9)
ALP (IU/L)a 386.6 (409.2)
γGTP (IU/L)a 103.7 (173.1)
T-Bil (mg/dl)a 0.6 (0.8)
C reactive protein (mg/dl)a 5.6 (6.4)
Daily dose (mg/day)a 273 (89.8)
Trough concentration (μg/ml)a 3.2 (2.3)
Trough concentration collection date (after initial dose)a
with loading dose 9.7 (13)
without loading dose 11.1 (9.5)
Purpose of voriconazole administration
prophylaxis/treatment
3/60





aA cumulative total of 77 samples
These data were collected at the time of initial voriconazole administration
Fig. 1 Relationship between voriconazole dosages per patient
weight and voriconazole trough concentration. Each point represents
a measurement. The linear regression curve is presented with
coefficient of determination (r2)
Fig. 2 Comparison of mean voriconazole concentration/dose ratio.
A scatter plot of voriconazole concentration/dose ratio from 77 samples
for 63 patients without coadministration of glucocorticoid (n= 49) and
with coadministration of glucocorticoid (n= 28). Solid line means mean
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0.53–0.82, p < 0.05), cutoff value 2.7 g/dl (sensitivity
61.9 %, specificity 73.7 %) (Fig. 3).
Adverse effects
Incidence of hepatotoxicity, visual disturbance, and neuro-
toxicity were 20.3, 43.5, and 22.6 %, respectively. Twelve
episodes of hepatotoxicity were observed: grade 2, six;
grade 3, six. Summary of hepatotoxicity were: grade 2
elevation of ALT, one; of ALP, two; of γGTP, four; grade 3
elevation of ALT, one; of ALP, two; of γGTP, six. The
voriconazole trough concentration were significantly
higher in patients with grade 2–3 hepatotoxicity than in
patients without, whereas no significant difference was
seen in visual disturbance and neurotoxicity (Fig. 4).
Discussion
The results of the present study have shown that CRP
elevation and hypoalbuminemia decreased voriconazole
clearance and that concomitant glucocorticoid adminis-
tration increased voriconazole clearance. In multiple
linear regression analysis, we did not detect the presence
of multicolinearity between CRP and glucocorticoid
administration (variance inflation factors < 2), suggesting
that CRP and concomitant glucocorticoid administration
should be independent of each other in affecting
voriconazole clearance. Although these two factors are
independent, we speculate these factors might be asso-
ciated with alteration of metabolism of voriconazole;
elimination of voriconazole is mainly by metabolism of
CYP2C19 dominantly and of CYP3A4 and CYP2C9
being involved to a much lesser extent [1–4].
Michael et al. retrospectively investigated therapeutic
drug monitoring of voriconazole in a cohort of 201 pa-
tients [9]. They identified by multiple linear regression
analysis that the use of a systemic glucocorticoid was
associated with significantly reduced voriconazole blood
concentrations. They hypothesized that glucocorticoid
up-regulated CYP2C19 and CYP3A4 expression since
some in vitro [16, 17] and in vivo [18, 19] studies have
shown that glucocorticoid can bind to and activate the
pregnane X receptor, one of the nuclear receptors which
plays a role in inducing cytochrome P450 expression,
including CYP2C19 and CYP3A4, resulting in the
increase of metabolism by the enzymes.
Another study has shown that voriconazole clearance
significantly decreased in a limited number of patients
with CYP2C19 poor metabolizer and heterozygous exten-
sive metabolizer when coadministered with erythromycin,
a known CYP3A4 inhibitor [12]. In our study, of the three
patients who administered concomitant glucocorticoid,
C/D-ratio of one patient was considerably increased by
discontinuation of glucocorticoid (Table 3, Case 1), and
C/D-ratios of the two patients were considerably
decreased by start of glucocorticoid (Table 3, Cases 2
and 3). They might be poor metabolizer of CYP2C19,
resulting in the prominent increase of voriconazole
metabolism due to CYP3A4 induction, although we did
not perform the allele analysis of any gene of the
patients.
Zordoky et al. reported that nuclear factor-κB plays a
crucial role in the regulation of cytochrome P450
through several mechanisms and this role can explain
the altered cytochrome P450 regulation in many condi-
tions [20]. They suggested that in inflammation status,
nuclear factor-κB-repressing factor is activated and
cytochrome P450 expression is decreased. A significant
decrease in voriconazole clearance observed in patients
with elevated CRP level in our study. Other studies
reported the inflammation is associated with higher
voriconazole trough concentrations [13, 21], congruent
with our results. Therefore, higher voriconazole trough
concentrations in inflammatory patients might be related
Table 2 Factors associated with a significant change in vorizconazole clearance identified from multiple linear regression analysis
95 % Confidence interval
Model term Coefficient Lower Upper Variance inflation factors p value
Albumin (g/dl) −0.19 −0.36 −0.03 1.55 <0.05
C reactive protein (mg/dl) 0.02 0.004 0.04 1.51 < 0.05
Glucocorticoid administration −0.25 −0.45 −0.05 1.18 < 0.05
Table 3 Change of voriconazole concentration and clearance about the patient with and without glucocorticoid administration
Patient Case. 1 Case. 2 Case. 3
Pre Post Pre Post Pre Post
Glucocorticoid mPSL 62.5 mg bid - - DEX 20 mg - PSL 20 mg
Daily dose (mg/day) 300 300 200 150 400 200
Trough concentration (μg/ml) 4.03 7.85 3.37 0.5 3.22 0.1
C/D-ratio 0.82 1.6 0.88 0.17 0.43 0.03
Abbreviations: mPSL methylprednisolone, DEX dexamethasone, PSL prednisolone, bid twice daily
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to the above mechanism, since elevated CRP level and
hypoalbuminemia are regarded as markers for inflamma-
tory status.
In addition, we undertook an ROC analysis for predic-
tion of risk of toxic voriconazole level on the basis of CRP
and Alb. The results suggest that CRP and Alb should be
useful for screening of toxic voriconazole level. In particu-
lar, in most cases, voriconazole concentrations reached
toxic levels when the CRP and Alb values of the patients
were over the cutoff values described below (Fig. 3c). Con-
sequently, careful monitoring of voriconazole concentra-
tion and side effects are required for patients with both
elevated CRP level and hypoalbuminemia. From our
analysis, the cutoff values of CRP and Alb were 4.7 and 2.7
respectively. Statistically, these cutoff values are useful for
prediction of toxic voriconazole level, although the value of
4.7 of CRP is less clinically important, since the value is
common level of infectious diseases. Voriconazole concen-
trations in patients with hepatotoxicity were significantly
higher than those without. In addition, the concentrations
of voriconazole in 75 % of patients with hepatotoxicity
were over 4 μg/ml. This result suggests that voriconazole
trough concentration over 4 μg/ml should be avoided,
supported by previous reports [8, 10].
A limitation of the present study is that CYP2C19
polymorphism was not available. However, Geist et al.
found an enormous (88 %) interpatient variability in
Fig. 3 Receiver operating characteristic (ROC) curves for predicting
risk of toxic voriconazole level on the basis of CRP (a) and Alb (b);
relationships of toxic voriconazole level with CRP and Alb (c). The
true-positive rate represents the proportion of true positives that are
correctly classified as positive. The false-positive rate represents the
proportion of true negatives that are incorrectly classified as positive.
True-positive rate = true positives/(true positives + false negatives).
False-positive rate = false positives/(false positives + true negatives).
Closed circles represent patients with toxic voriconazole level and open
circles represent patients without toxic voriconazole level. 95 % CI, 95 %
confidence interval
Fig. 4 Relationships between voriconazole concentration and toxicities.
A scatter plot of voriconazole concentrations from all 63 patients. Closed
circles represent patients with toxicity and open circles represent patients
without toxicity. Closed diamond represents patients with Grade 3
hepatotoxicity. Solid line means mean. One patient was not assessed for
visual disturbance and neurotoxicity because of the administration of a
sedative. Four patients were not assessed for hepatotoxicity because of
liver dysfunction due to primary disease. A significant difference was
seen in voriconazole mean trough concentration between patients with
grade 2-3 hepatotoxicity and those without: 5.69 (SD 2.27) vs. 3.0 (SD
2.07), p< 0.001. No significant difference was seen in voriconazole mean
trough concentration between patients with other adverse events
and those without: visual disturbance - 3.48 (SD 1.79) vs. 3.44
(SD 2.7), p = 0.94; neurotoxicity - 4.2 (SD 2.85) vs. 3.27
(SD 2.11), p = 0.18
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voriconazole trough concentrations, although none of
the patients were classified as a CYP2C19 poor
metabolizer. They noted that the high variability
resulted from contributing factors, including changes
in drug absorption, co-medication, and disease status
[22]. Further studies are needed to clarify contributing
factors in patients with known genetic polymorphisms
of the cytochrome P450 isoenzymes.
Conclusion
We evaluated patient-specific factors affecting voricona-
zole clearance and showed that increased CRP level and
decreased Alb level were significant predictors of
decreased voriconazole clearance, and coadministration
of glucocorticoid was found to be a significant predictor
of increased voriconazole clearance. It is not practical to
examine CYP2C19 alleles due to the cost, so it is difficult
to consider CYP2C19 polymorphism in therapeutic drug
monitoring in routine practice. Therefore, we propose that
early measurement of voriconazole concentration before
the plateau phase should lead to the avoidance of toxic
voriconazole level in patients with elevated CRP level and
hypoalbuminemia.
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